| Document |
Document Title |
|
WO/2023/117879A1 |
The present invention relates to a method for the treatment of FGFR-related bone repair and bone formation and quality impairment. The inventors provide data confirming that abnormal activation of the FGFR3 signaling impairs the bone for...
|
|
WO/2023/115311A1 |
A pharmaceutical composition, comprising: a. a liquid oil; b. at least one pharmaceutically acceptable gelator, wherein the gelator is selected from: a fatty acid, a fatty alcohol, a fatty acid glyceride, a sterol, a sorbitol fatty acid ...
|
|
WO/2023/117768A1 |
The present invention relates to methods for treating a cancer comprising administering to a subject in need thereof an effective amount of a (i) first anti-cancer agent, (ii) an agent sensitizing and/or potentiating the cancer to the fi...
|
|
WO/2023/115757A1 |
An application of adenosine or adenosine monophosphate in preparation of anti-infective drugs. Adenosine or adenosine monophosphate can significantly improve the sensitivity of clinical bacteria such as Escherichia coli, Aeromonas hydrop...
|
|
WO/2023/118126A1 |
The present invention relates to a combination of selective blockers of TASK-1 and TASK-3 channels, in particular substituted imidazo[1,2-a]pyrimidine and substituted imidazo[1,2-a]pyridine derivatives of formula (I) and norepinephrine r...
|
|
WO/2023/118123A1 |
The present invention relates to a combination of a noradrenaline reuptake inhibitor and α2-Adrenoceptor subtype C (alpha-2C) antagonists, in particular substituted heterocyclic carboxamides of formula (I) for the treatment and/or proph...
|
|
WO/2023/116671A1 |
Provided is a method and a medicament for treating amyotrophic lateral sclerosis (ALS) in a subject in need thereof, comprising administering to the subject an effective amount of one or more active agents selected from the group consist...
|
|
WO/2023/118893A1 |
There is provided herein compounds of formula I : (I) and pharmaceutically-acceptable salts and/or detectably-labelled derivatives thereof, wherein RA, RB, X, Y, n and m have meanings as provided in the description, together with formula...
|
|
WO/2023/119230A1 |
Provided are compositions comprising (1) a physiologically effective amount (e.g., a cosmetically effective amount or therapeutically effective amount) of a coagulation pathway modulation component (CP-MC), which modulates a protein C ac...
|
|
WO/2023/117855A1 |
The present invention relates to a method for the treatment of FGFR-related bone repair and bone formation and quality impairment. The inventors provide data confirming that abnormal activation of the FGFR3 signaling impairs the bone for...
|
|
WO/2023/121103A1 |
The present invention relates to an agent capable of inhibiting the activity or enhancing the expression of various cancer-related RNAs in TAMs and cancer cells, and to a dual target drug delivery system capable of binding to both macrop...
|
|
WO/2023/116283A1 |
Provided is an Enterococcus lactis with the deposit number of CCTCC NO: M20211220, which is deposited in the China Center for Type Culture Collection. The provided Enterococcus lactis of CCTCC NO: M20211220 can still ensure a survival ra...
|
|
WO/2023/118085A1 |
The present disclosure relates to methods of treating a brain tumour or a neuroblastoma in a patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of a substituted azaquinolone com...
|
|
WO/2023/109836A1 |
Disclosed is an ultrasonically-enhanced continuous and large-scale production method for nano-formulations. Specifically disclosed is a preparation system for continuous production of nano-formulations, comprising (a) a first pipe, (b) a...
|
|
WO/2023/109906A1 |
A pharmaceutical composition for inflammatory skin diseases, a preparation method therefor, and a use thereof in preparation of drugs for treating and/or preventing immunological, inflammatory and autoimmune diseases. The pharmaceutical ...
|
|
WO/2023/114264A1 |
Disclosed are methods, uses, and combinations for treating high-risk metastatic hormone-sensitive prostate cancer, the methods, uses, and combinations including the administration of (i) a CDK4 and 6 inhibitor or a pharmaceutically accep...
|
|
WO/2023/114170A1 |
The present invention relates to treatment of chronic kidney disease by administering to patients in need thereof a compound of formula (I) and pharmaceutically acceptable salts thereof, wherein Cy, R1and R2 are as defined herein. The in...
|
|
WO/2023/114231A1 |
The genomes of cancer cells harbor somatic mutations imprinted by the activities of different mutational processes. Most single-base substitutions and small insertions and deletions (indels) are independently scattered across the genomic...
|
|
WO/2023/112975A1 |
Provided is a lymphocyte function promoter. The lymphocyte function promoter contains at least one selected from the group consisting of a compound represented by general formula (1), a salt thereof, and a solvate of the same.
|
|
WO/2023/111810A1 |
The present disclosure relates to the treatment of cancer and/or cancer-associated disease. Certain aspects relate to the treatment of an individual having cancer or cancer-associated disease by administering to the individual a combinat...
|
|
WO/2023/112992A1 |
The present disclosure provides a safe immunity control method. Provided is a pharmaceutical composition that contains CTLA-4 or a nucleic acid encoding same, or a functional equivalent thereof, or a factor that induces at least one th...
|
|
WO/2023/112678A1 |
Provided is a composition with which it is possible to enhance the percutaneous absorption of a crystalline water-soluble drug without temporarily irritating the skin as with an amphoteric surfactant. The composition of the present dis...
|
|
WO/2023/109784A1 |
The present invention relates to the technical field of biomedicines, and in particular, to a use of an SGLT2 inhibitor in preparation of a drug for preventing and treating male reproductive dysfunction. Research results of the present i...
|
|
WO/2023/114225A1 |
Provided herein is a combination therapy for use in a method of treating mantle cell lymphoma in a patient in need thereof.
|
|
WO/2023/113477A1 |
The present invention provides pharmaceutical combinations comprising (a) a TTK/PLK1 inhibitor (i.e. a compound of formula (I) or a pharmaceutically acceptable salt thereof as defend in the claims) and (b) a taxane anticancer drug or a p...
|
|
WO/2023/108563A1 |
Provided is a pharmaceutical composition for enhancing the anti-tumor effect of an EZH2 inhibitor. The pharmaceutical composition comprises an EZH2 inhibitor and an SD1 inhibitor, wherein the SD1 inhibitor enhances the effect of the EZH2...
|
|
WO/2023/110855A1 |
The present invention provides pea protein and compositions comprising pea protein for use in the prevention and/or treatment of autoimmune arthritis. The invention also provides said compositions for use in combination therapy with an a...
|
|
WO/2023/111173A1 |
The present invention relates to the treatment of resistant leukemia. The inventor studied APL cellular heterogeneity by integrating scRNA-seq and scATAC-seq data obtained from PLZF-RARA transformed promyelocytes treated with RA. Establi...
|
|
WO/2023/114224A1 |
The present disclosure relates to compositions, kits, and methods of treating CNS diseases and disorders using a combination of a muscarinic receptor positive modulator and an NMDA receptor positive allosteric modulator.
|
|
WO/2023/108700A1 |
A biomimetic drug-loaded nanoparticle specifically targeting an inflammatory region after pulsed field ablation and a preparation method. The biomimetic drug-loaded nanoparticle comprises: a drug-loaded liposome and a neutrophil membrane...
|
|
WO/2023/109563A1 |
The present invention relates to a cabazitaxel prodrug anti-tumor preparation, designs and synthesizes a cabazitaxel-fatty alcohol small molecule prodrug containing different fatty alcohol side chains and different connecting chains of g...
|
|
WO/2023/113129A1 |
One aspect relates to a pharmaceutical composition for the prevention or treatment of blood cancer, comprising a surfeit locus protein 4 (SURF4) inhibitor. The composition according to one aspect inhibits SURF4 to increase the expression...
|
|
WO/2023/109290A1 |
The present invention provides an oil composition. The oil comprises a microbial oil and a vegetable oil. Calculating on the basis of the total weight of the composition, the composition comprises at least 0.5 wt% of the oils. The presen...
|
|
WO/2023/104048A1 |
The present invention relates to the field of biomedicine. Disclosed are a brain tumor-targeting polypeptide, a derivative thereof and an application thereof. Specifically disclosed is use of the polypeptide in the preparation of a brain...
|
|
WO/2023/105076A1 |
The present invention relates to the prevention and/or treatment of cancer in a subject, wherein the subject is administered a Gram-negative bacterium in a first treatment phase and a chemotherapy agent in a second treatment phase.
|
|
WO/2023/105227A1 |
There is provided a pharmaceutical or veterinary formulation comprising: (a) a biologically-active agent in admixture with a pharmaceutically- or veterinarily- acceptable extended-release component; (b) an antiinflammatory agent; and (c)...
|
|
WO/2023/107979A1 |
Provided herein are compositions and methods for the treatment of a cancer. Said compositions comprise an FGFR kinase inhibitor. Some embodiments comprise combination therapy featuring the FGFR kinase inhibitor with at least one oncology...
|
|
WO/2023/107525A1 |
Disclosed are methods, uses, and combinations for treating hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer in patients previously treated with a CDK4 and 6 i...
|
|
WO/2023/104402A1 |
A composition for use in the treatment and/or prevention of COVID-19 disease in a subject, wherein the composition comprises milk protein and the milk protein comprises Serum Protein Concentrate (SPC) and/or Whey Protein Concentrate (WPC...
|
|
WO/2023/103835A1 |
An ophthalmic preparation of a tyrosine kinase inhibitor suitable for eye drop administration is prepared from the following raw materials and adjuvants in parts by weight: active ingredient: 0.5-1.5 parts of a tyrosine kinase inhibitor,...
|
|
WO/2023/104227A1 |
The present invention discloses ginsenosides used alone or in combination with nucleoside/nucleotide analogues for use in the treatment or prophylaxis of chronic hepatitis B virus infections.
|
|
WO/2023/104380A1 |
The present invention relates to nanocontainers for the synergistic transport of lipophilic and hydrophilic active substances or detection reagents. In particular, the nanocontainers according to the invention offer a possibility for the...
|
|
WO/2023/106273A1 |
The present invention addresses the problem of developing a composition having antiviral activity by utilizing the immunological action of intestinal bacteria as well as the action thereof against infection with viruses including influen...
|
|
WO/2023/107697A1 |
Provided herein are methods for treating sickle cell disease comprising administering Compound (I), a modulator of hemoglobin, according to certain dosing regimens.
|
|
WO/2023/105325A1 |
The present invention relates to a composition for oral use comprising sulodexide and one or more flavonoids as active principles, in the treatment of a vascular disease, in particular in the treatment of the chronic venous insufficiency...
|
|
WO/2023/104151A1 |
The present invention relates to a combination of an FAK inhibitor, an anthracycline chemotherapeutic drug, and an immune checkpoint inhibitor to treat tumors. The present invention also relates to a combination of an FAK inhibitor and a...
|
|
WO/2023/105283A1 |
The present invention relates to nucleoside reverse transcriptase inhibitors (NRTI) or their pharmaceutically acceptable salts for use in (a) the treatment of Down syndrome or the consequences thereof or (b) the prevention, inhibition of...
|
|
WO/2023/103137A1 |
An orthoester mixture pharmaceutical excipient, relating to the field of pharmaceutical excipients, and mainly obtained by mixing different orthoester compounds in different proportions or by mixing orthoester compounds with biocompatibl...
|
|
WO/2023/103963A1 |
A cell linker and a cell modified by an agent linked thereto, wherein the agent is conjugated to a phospholipid via a sortase recognition motif, and the phospholipid with the conjugated agent is incorporated into the cell membrane of the...
|
|
WO/2023/104024A1 |
Provided are a mineralized drug-loaded yeast bionic micro-nano robot, and a preparation method therefor and the use thereof. The mineralized drug-loaded yeast bionic micro-nano robot comprises a yeast cell, a biological mineralized nano ...
|
